Skip to Main Content
Contact Us

Catalyst Clinical Research Earns Spot on Inc. 5000 List of Fastest-Growing Private Companies

August 15, 2023

CRO Ranks in Top Half of Annual List

Revenue increase and bump in employee headcount credited for recognition. 

Wilmington, N.C., 15 August 2023 – Catalyst Clinical Research, a market-leading provider of clinical research services, was named in the 2023 Inc. 5000 list of the nation’s fastest-growing private companies for the fourth consecutive year. Catalyst remained in the top half of the companies recognized, ranking at 2,115.

This recognition follows Catalyst being named to Inc.’s 2023 Best Places to Work list for the second consecutive year. These back-to-back accolades showcase Catalyst’s growth during a challenging year overall for the clinical research industry while continuing to invest in a culture-first mindset to support its employees.

Being acknowledged for the fourth consecutive year directly stems from the dedication of our entire Catalyst team and the loyalty of our clients and trusted partners. Our ongoing growth is a product of our people-first, value-centered culture. We look forward to continuing our commitment to delivering high-quality services to the global biopharmaceutical market.

Nick Dyer
Catalyst CEO

Last year, Catalyst announced its broad expansion of its European footprint with the acquisition of Aptus Clinical, followed by further expansion into the Asia-Pacific region in 2023. In July, the company completed its acquisition of Genpro Research and announced the opening of its first-ever Australia office earlier in the year. Leaders within the organization are delighted by the Inc. 5000 honors and feel the expansions are a byproduct of championing the company’s core values and working to partner with like-minded organizations.

Melissa Church, Senior Vice President, Strategy and Solutions added, “Our company has gained talented global team members through both organic growth and acquisition which allows us to meet the growing requests from our clients to deliver multi-region solutions. In addition, our commitment to our values-driven company culture makes us a CRO employer of choice. It’s exciting to see our strategy come to life and be recognized by Inc. Magazine.”

Catalyst is one of just 55 North Carolina-based companies and one of only 3 Wilmington, NC-based companies to rank on this year’s Inc. 5000 list, from thousands of submissions. Complete results, including company profiles sorted by industry, region, and other criteria, can be found at

For more information on Catalyst, visit

About Catalyst Clinical Research

Catalyst is a clinical research organization (CRO) that provides highly customizable solutions to the global biopharmaceutical industry through two established, branded solutions: Catalyst Oncology and Catalyst Flex. The company provides full-service oncology CRO offerings through Catalyst Oncology and multi-therapeutic Client- or Catalyst-managed functional services through Catalyst Flex. With around 1000 staff and offices in the United States, Europe, and Asia-Pacific regions, Catalyst’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping customers drive breakthrough clinical studies by leveraging expert teams and innovative technologies. Visit Catalyst online at Follow us on Facebook, and LinkedIn: @CatalystCR.

Catalyst is a portfolio company of QHP Capital, a leading healthcare and life sciences investment firm.